Modality
Degrader
MOA
Menini
Target
CFTR
Pathway
Incretin
MesoCervical CaSCD
Development Pipeline
Preclinical
~Jan 2014
→ ~Apr 2015
Phase 1
~Jul 2015
→ ~Oct 2016
Phase 2
Jan 2017
→ Jul 2030
Phase 2Current
NCT07692754
1,468 pts·Meso
2023-12→2030-07·Terminated
NCT07392796
541 pts·SCD
2017-01→2029-01·Recruiting
2,009 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-01-112.8y awayPh3 Readout· SCD
2030-07-134.3y awayPh3 Readout· Meso
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Termina…
Catalysts
Ph3 Readout
2029-01-11 · 2.8y away
SCD
Ph3 Readout
2030-07-13 · 4.3y away
Meso
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07692754 | Phase 2/3 | Meso | Terminated | 1468 | HbA1c |
| NCT07392796 | Phase 2/3 | SCD | Recruiting | 541 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Doxasotorasib | Samsung Biologics | Phase 2/3 | CFTR |